NEW YORK (
CHANGE IN RATINGS
(AMGN - Get Report)
downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Few upside drivers remaining in 2012.
upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $15 price target. Moxi should still achieve full-year sales targets.
Arris Group downgraded to hold at TheStreet Ratings.
downgraded to hold at TheStreet Ratings.
(BIG - Get Report)
rated new Neutral at JP Morgan. $48 price target. Company is turning sales around buy management has a choppy track record.
upgraded at Jefferies to Buy from Hold, Jefferies said. $65 price target. Ethanol and AO+ should buoy shares.
(CIT - Get Report)
upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $48 price target. Company is moving back toward an investment-grade credit rating.
downgraded at JP Morgan from Neutral to Underweight, JP Morgan said. $66 price target. Customer inventories are likely high heading into the new year.
(CSCO - Get Report)
downgraded at ISI from Buy to Neutral, ISI Group said. Valuation call, based on a $22 price target.
downgraded at Jefferies to Hold from Buy, Jefferies said. $24 price target. Too much uncertainty around lease up.
rated new Overweight at JP Morgan. $100 price target. Company can generate sustainable 20% annual earnings growth.
(IM - Get Report)
downgraded at Needham from Buy to Hold, Needham said. Valuation call, based on a $20 price target.
downgraded at JP Morgan to Underweight, JP Morgan said. $30 price target. Company slashed its guidance.
(JOY - Get Report)
downgraded at Jefferies to Hold from Buy, Jefferies said. $90 price target. Shares have met price target.
(MMM - Get Report)
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, based on a $95 price target.
downgraded at Jefferies to Hold from Buy, Jefferies said. $28.50 price target. Reflecting the prospect of Eastman's acquisition of Solutia for $22 in cash and 0.12 shares.
upgraded at Piper to Overweight, Piper Jaffray said. $37 price target. Stock is already factoring in higher potential competition.
downgraded at Benchmark from Buy to Hold, Benchmark said. $31 price target. Growth and margin expansion may still be a year away.